Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Speaking about NWBO’s publication, I just came across a rather snarky commentary of the British press because they printed favorable comments on DCVax:
“CANCER
A Glioblastoma Vaccine? Not Yet.
By Derek Lowe 30 May, 2018
If you get your biomedical breaking news from the British press, you will have heard all about a very promising vaccine treatment for glioblastoma.” (“Remarkably promising” – BBC. “Could add years” – The Guardian. And there’s the Daily Mail (naturally), The Independent, and more). That would be good news, because that’s a terrible diagnosis with very little in the way of effective treatment. But if you get your breaking biomedical news from the British press, then I am very sorry for you.”
Complete article:
http://blogs.sciencemag.org/pipeline/archives/2018/05/30/a-glioblastoma-vaccine-not-yet
Mr. Lowe also wrote another snide article in September 2014 dissing NWBO but schmoozing AF.
http://blogs.sciencemag.org/pipeline/archives/2014/09/29/the_case_of_northwest_biotherapeutics
I just offer the aforementioned for record keeping purposes to those who retain files.
Has the new date for the NWBO/BMS clinical trial been posted? It is now September 1, 2018. Apologies if this is repeat.
https://clinicaltrials.gov/ct2/show/NCT03014804?term=NCT03014804&rank=1
By THE EDITORS OF KIPLINGER'S PERSONAL FINANCE
June 29, 2018
The stock market and the bond market both close early on Tuesday, July 3, 2018, the day before the Fourth of July holiday. The stock market closes early at 1 p.m. Eastern Time, and the bond market closes early at 2 p.m. ET. The stock market and the bond market are both closed on Wednesday, July 4, for the Independence Day holiday. All markets re-open and resume regular trading hours on Thursday, July 5.
SEC filings
I agree, however, it’s difficult to conceive that the US will compromise their leadership status in life sciences
Should the UK take the lead in approving and marketing NWBO’s cancer therapy, then bravo for them - IMO the UK will not only further their advancement in ATMP accessibility, they will reap those bonus dollars of which you speak via medical tourism.
US proposes reorganization under which FDA would be renamed Federal Drug Administration
https://www.firstwordpharma.com/node/1574260?tsid=28®ion_id=6
A skill perhaps honed in writing thesis and dissertation papers.
Coincidentally, I just came across a new clinical trial with Neon Therapeutics and Merck
https://clinicaltrials.gov/ct2/show/NCT03380871
I understand that Medscape Medical News is part of the WebMD Network, correct? Quite an audience. We aren’t Northwest Pharmaceuticals, Inc. If Medscape makes a correction, NWBO will receive additional exposure.
Of interest: Keytruda headlines this morning - 6.13.2018
Merck & Co.'s Keytruda gains accelerated FDA approval for advanced cervical cancer
https://www.firstwordpharma.com/node/1572223?tsid=28®ion_id=6
We are doing that on Twitter, Facebook and LinkedIn. Now we also take the fight to the shorties and those spreading misinformation in the public arena. Not going to take this quietly with the manipulators.
CHARGE!
Beautiful - should be shown in every elementary classroom.
Thank you, Sojourner 55
Tryn2
According to the description of Mr. Feuerstein's topic, it appears that the focus will be on publications. Note that last sentence in the following:
Description
As the media industry continues to evolve, we’re seeing certain established publications fall to the wayside while new media models rise to the top — with fresh styles of reporting that increasingly involve interactive and social components. It’s forcing biotech executives to rethink their media outreach strategies and be more transparent than ever with the journalists covering their industry. In this session, you’ll hear directly from today’s life science reporters and media experts on the new publication models that are gaining steam, how to best engage with journalists in your areas of expertise, and what smart tactics you can use gain exposure for your company in top industry publications. A lively discussion will include questions from the audience, and will be moderated by a seasoned media expert who’s primed with compelling case studies.”
.
Doc…..
Thank you for your valuable and quality posts on this NWBO IHub message board.
“You’re a Good Man, Charlie Brown”…Charles M. Schulz
I’ve posted this previously - AF is scheduled to speak at the Bio Conference in Boston:
“Bio Int’l Convention 6.4-7.2018 Boston
4:15PM-5:15PM…..June 5
Corporate Best Practices & Leadership
New Era of Biotech Journalism
Speakers
Adam FeuersteinNational Biotech Columnist atStat News
Lisa LaMottaSenior Editor atBioPharma Dive
Lydia RamseyReporter atBusiness Insider
Ian StoneSenior Vice President atCanale Communications
https://mybio2018.zerista.com/event?owner_id=2011153&owner=other&event_order=start&event_page=7
Interesting: I note that Mr. Feuerstein will be at the Boston Convention on June 5th.
“Bio Int’l Convention 6.4-7.2018 Boston
4:15PM-5:15PM…..June 5
Corporate Best Practices & Leadership
New Era of Biotech Journalism
Speakers
Adam FeuersteinNational Biotech Columnist atStat News
Lisa LaMottaSenior Editor atBioPharma Dive
Lydia RamseyReporter atBusiness Insider
Ian StoneSenior Vice President atCanale Communications
https://mybio2018.zerista.com/event?owner_id=2011153&owner=other&event_order=start&event_page=7
Description
As the media industry continues to evolve, we’re seeing certain established publications fall to the wayside while new media models rise to the top — with fresh styles of reporting that increasingly involve interactive and social components. It’s forcing biotech executives to rethink their media outreach strategies and be more transparent than ever with the journalists covering their industry. In this session, you’ll hear directly from today’s life science reporters and media experts on the new publication models that are gaining steam, how to best engage with journalists in your areas of expertise, and what smart tactics you can use gain exposure for your company in top industry publications. A lively discussion will include questions from the audience, and will be moderated by a seasoned media expert who’s primed with compelling case studies.”
.